# US 2021/0277050 A1 · Ophthalmic compositions and methods for the treatment of eye disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277050 A1
- Document ID: US20210277050A1
- Status: Published application
- Kind: A1
- Application number: 17/250,281
- Filed: 2019-06-18
- Published: 2021-09-09
- Earliest claimed: 2018-06-27
- Assignees: Cellix Bio Private Limited
- Applicants: Cellix Bio Private Limited
- Inventors: Mahesh Kandula
- Web page: https://patentgrep.com/patent/US20210277050A1

## CPC

- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- C07J 33/002: {not condensed}
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- C07C 229/08: the nitrogen atom of the amino group being further bound to hydrogen atoms
- C07D 217/10: Quaternary compounds
- C07D 339/04: having the hetero atoms in positions 1 and 2, e.g. lipoic acid
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07J 41/0055: {the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives}
- C07J 41/0088: {containing unsubstituted amino radicals}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0043: {Nose}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI formula XII, formula XIII, formula XIV, formula XV, formula XVI, or formula XVII and the methods for the treatment of eye diseases may be formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD.

## Claims

### Claim 1

A compound of formula I
and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof,
wherein
R1 independently represents Null,
R2 represents

### Claim 2

A compound of formula II
and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof,
wherein,
R1 independently represents Null,
R2 represents
RH independently represents

### Claim at position 3

-17. (canceled)

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein said pharmaceutical administration is formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye or oGVHD.

### Claim 21 (depends on 2)

A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22, wherein said pharmaceutical administration is formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye or oGVHD.

### Claim at position 10

-68. (canceled)

### Claim 69

A compound of the structure selected from a group consisting of

### Claim 70 (depends on 69)

A pharmaceutical composition comprising a compound of claim 69, and a pharmaceutically acceptable carrier.

### Claim 71 (depends on 70)

The pharmaceutical composition of claim 70, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.

### Claim 72 (depends on 71)

The pharmaceutical composition of claim 71, wherein said pharmaceutical administration is formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye or oGVHD.
